FDA Brief

Warning letters Drugs

FDA warning letter to

Shimoga Chemicals

High riskIssued Jul 13Posted Jul 21Center for Drug Evaluation and Research (CDER)

FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

What happened

FDA inspected Shimoga Chemicals' drug manufacturing facility in Sangli, India, from January 19 to 23, 2026, and found significant deviations from CGMP, the FDA's current good manufacturing practice rules for drugs. Investigators found unreported laboratory sample injections, including an out-of-specification strength result for clomiphene citrate USP batch CC/005/24-25 that was released and distributed, plus inadequate sampling, method verification, process validation, cleaning, quality-unit investigations, stability, and training. The firm recalled clomiphene citrate USP on May 14, 2026, and FDA placed its drugs on Import Alert 66-40 on June 2, 2026.

What FDA found

  1. The firm did not record some laboratory sample injections, including an out-of-specification strength result for batch CC/005/24-25, which was released and distributed.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. Batch records did not specify sample quantities, locations, methods, or timing, and samples were taken from arbitrary locations.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The firm did not verify any test methods, including the residual solvent method used by its contract laboratory.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. Process validation reports did not reflect actual manufacturing and did not address hold times.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  5. Cleaning procedures for shared equipment lacked defined acceptance criteria, specific methods, materials, contact times, and validation.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  6. The quality unit did not adequately investigate out-of-specification events, ensure stability data supported expiry, or ensure personnel were trained.

    21 CFR parts 210 and 211

What FDA wants

FDA asks Shimoga Chemicals to correct the deviations promptly and provide comprehensive assessments and remediation plans for its laboratory, validation, cleaning, quality-unit, stability, training, and data-integrity failures, and to engage a qualified CGMP consultant before resuming U.S. manufacturing; the provided letter text does not show a response deadline.

Who should pay attention

  • compounding pharmacies using clomiphene citrate USP
  • API buyers and distributors
  • quality teams auditing suppliers

This is a summary. Read the original letter on fda.gov.

Shimoga Chemicals's FDA history

Recalls in the last 12 months

Jul 15 Class II Shimoga Chemicals
Drug
Clomiphene Citrate USP Active Pharmaceutical Ingredient (CAS : 50-41-9), Net Weight a)1 KG (NDC 84849-000-01), b) 500 g (NDC 84849-000-02), (c) 100 g (NDC 84849-000-03), Rx Only, Shimoga Chemicals Address -W-57A, MIDC Ku…
cGMP deviations

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk